Summary of Key Points from the Conference Call Company Overview - The company discussed its performance for 2025 and provided guidance for 2026, indicating a strong growth trajectory in various business segments, particularly in the chemical macromolecule and emerging business sectors [2][3][16]. Financial Performance - In 2025, the company achieved a revenue of 6.67 billion yuan, a year-on-year increase of 14.9%, aligning with the growth guidance of 13%-15% [3][16]. - The adjusted net profit for 2025 was 1.253 billion yuan, reflecting a growth of over 50% compared to 2024 [3][16]. - The gross profit margin for 2025 was stable at 42%, with a net profit margin of 17%, up by 0.6 percentage points [3][16]. Order Backlog and Growth - As of Q1 2026, the company had an order backlog of 1.385 billion USD, a 31.7% increase year-on-year, driven primarily by the macromolecule business [2][3][16]. - The fourth quarter of 2025 saw a significant increase in orders, marking the highest growth rate in five quarters, attributed to new business orders [2][20]. Business Segment Performance Small Molecule Business - Revenue for the small molecule segment in 2025 was 4.735 billion yuan, a 3.6% increase, with a gross margin of 46.8% [4][6]. - The company is involved in five GLP-1 clinical projects, with two in late-stage development [6][20]. Emerging Business - The emerging business segment generated 1.929 billion yuan in revenue, a 57.3% increase, with a gross margin of 30.1%, up 8 percentage points from 2024 [4][6]. - Revenue from overseas markets in this segment grew by 240% [4][6]. Chemical Macromolecule Business - This segment saw a revenue increase of 123% to 1.028 billion yuan, with a backlog growth of 127.6% [4][6]. - The company is servicing 19 GLP-1 clinical projects, with eight in late-stage development [6][15]. Biopharmaceutical CDMO - The biopharmaceutical CDMO business nearly doubled its revenue to 294 million yuan, with a 55.6% increase in order backlog [9][10]. - The first ADC commercial workshop is expected to be delivered in Q2 2026 [10]. Capital Expenditure and Capacity Expansion - The company plans to invest 2.1 billion yuan in capital expenditures for 2026, with 70%-80% directed towards new business segments [2][19]. - The production capacity for solid-phase peptide synthesis is expected to expand to 69,000 liters by the end of 2026 [2][19]. Market Trends and Challenges - The company noted that the recent Middle East conflict has led to price increases in raw materials, but the overall impact on costs is manageable [17][18]. - There is a growing demand for new modalities in the CDMO market, particularly in conjugated drugs and peptides, indicating a positive outlook for future orders [21][22]. Outlook for 2026 - The company expects revenue growth of 19%-22% for 2026, with an additional 2-3 percentage points expected from constant currency adjustments [2][16]. - The gross margin for the emerging business is anticipated to improve further due to increased overseas revenue and enhanced delivery capabilities [18][22]. Conclusion - The company is well-positioned for continued growth across its various business segments, with a strong order backlog and strategic investments planned for capacity expansion and new business development [2][3][16][19].

Financial Overview - Total revenue for 2025 reached CNY 6.67 billion, a 14.9% increase from 2024 [74] - Adjusted net profit was CNY 1.25 billion, reflecting a 56.1% growth [12] - Gross profit margin stood at 42.0%, with an adjusted net profit margin of 18.8% [12] Business Segment Performance Small Molecule CDMO - Revenue from small molecule CDMO business was CNY 4.74 billion, a 3.6% increase year-on-year [19] - Gross margin for small molecule business was 46.8% [19] - The segment delivered 59 commercial projects and 515 clinical projects, including 70 Phase III projects [26] Emerging Business - Emerging business revenue surged to CNY 1.93 billion, a 57.3% increase [19] - International revenue from this segment exceeded CNY 850 million, growing over 240% [19] - Gross margin for emerging business improved to 30.1%, up 8.4 percentage points [19] Biologics CDMO - Revenue from biologics CDMO reached CNY 294 million, a 95.8% increase [41] - The segment executed 130 projects, including 5 BLA projects and 46 IND projects [41] Market Expansion - The company added over 300 new clients in 2025, enhancing its global market presence [20] - Revenue from multinational pharmaceutical companies was CNY 4.92 billion, accounting for 52% of total revenue [20] Future Outlook - Projected revenue growth for 2026 is estimated between 19% and 22% [70] - The company plans to invest approximately CNY 2.1 billion in capital expenditures to expand production capacity [70]

Company Overview - Aopu Mai Biotechnology Co., Ltd. plans to acquire 100% equity of Plenitude Biopharmaceutical Technology (Shanghai) Co., Ltd. for a total transaction price of 1.451 billion yuan [1] - Aopu Mai specializes in cell culture products and clinical new drug process development and production services (CDMO), with its main revenue sources being cell culture products and CDMO services [1] - In the first three quarters of 2025, Aopu Mai's cell culture product business generated revenue of 239 million yuan, a year-on-year increase of 32.56%, making it the company's "core pillar" [1] Industry Context - The biopharmaceutical CDMO industry is highly competitive, with significant market segmentation between comprehensive CDMO leaders and specialized institutions [1] - The number of companies in the industry is large, with leading enterprises having a much higher global revenue share compared to second-tier companies [2] - Mergers and acquisitions among mid-tier companies can help expand business capabilities and improve industry efficiency [2] Acquisition Details - Aopu Mai's acquisition of Plenitude Biopharmaceutical aims to enhance its CDMO service capabilities and expand its customer base by integrating Plenitude's resources [2] - Plenitude Biopharmaceutical reported revenue of 187 million yuan and a net profit of 23.86 million yuan in the first half of 2025 [2] - The acquisition involves 31 parties and will utilize a differentiated pricing model, including stock and cash payments, to facilitate the transaction [3] Strategic Importance - The acquisition is seen as a key decision for Aopu Mai to achieve its strategic goals and further integrate its business operations [4] - Analysts suggest that the synergy post-acquisition will primarily manifest in customer flow between early-stage and later-stage business units, potentially enhancing profitability and increasing the share of overseas business [5]

Core Viewpoint - Aopu Mai's acquisition of 100% equity in Pengli Biopharmaceutical Technology (Shanghai) Co., Ltd. for a total of 1.451 billion yuan is progressing, but concerns arise due to the expected goodwill of approximately 555 million yuan and the declining performance of Pengli Biopharmaceutical [1][3][4]. Group 1: Acquisition Details - The acquisition involves issuing shares and cash payments to 31 parties for the purchase of Pengli Biopharmaceutical's equity, with a transaction price of approximately 1.451 billion yuan [3]. - As of December 31 last year, Pengli Biopharmaceutical's book value of equity was 927 million yuan, with an assessed value of 1.452 billion yuan, resulting in an assessed increase of 525 million yuan, representing a 56.62% increase [3][4]. - Aopu Mai aims to leverage Pengli's clinical research client resources to promote its cell culture products and biopharmaceutical CDMO services, thereby expanding its potential customer base and early-stage research pipeline [3]. Group 2: Financial Implications - The expected goodwill of approximately 555 million yuan will account for 13.74% of Aopu Mai's total assets and 19.55% of its net assets as of the end of last year, and it represents 849.41% of the projected net profit for 2024 [4]. - Pengli Biopharmaceutical's revenue for 2023-2024 and the first half of this year was 318 million yuan, 331 million yuan, and 187 million yuan, with net profits of 59.75 million yuan, 44.51 million yuan, and 23.86 million yuan, respectively [5][6]. - The gross profit margins for Pengli Biopharmaceutical's main business were 47.3%, 42.98%, and 43.58%, indicating a decline due to factors such as revenue structure and pricing [6]. Group 3: Performance Risks - The independent director, Tao Hua'an, has repeatedly voted against the acquisition, expressing concerns about the necessity of the merger at this stage, which adds uncertainty to the transaction [1][8]. - The performance of Pengli Biopharmaceutical is under scrutiny, as its profitability is influenced by various factors, including policy environment and market demand, raising the risk of not meeting the promised net profit targets for 2025-2027 [6][7]. - Aopu Mai's own performance has shown a decline over the past two years, with revenues of approximately 243 million yuan, 297 million yuan, and 272 million yuan, and net profits of approximately 54 million yuan, 21 million yuan, and 49 million yuan for the same periods [7].

Core Viewpoint - Aopu Mai (688293) is progressing with its acquisition of 100% equity in Pengli Biopharmaceutical Technology (Shanghai) Co., Ltd. for a total of 1.451 billion yuan, but faces concerns regarding goodwill impairment and the declining performance of the target company [1][5][6]. Group 1: Acquisition Details - The acquisition involves issuing shares and cash payments to 31 parties for the purchase of Pengli Biopharmaceutical's equity, with a transaction price of approximately 1.451 billion yuan [5]. - After the transaction, Aopu Mai expects to add about 555 million yuan in goodwill, which represents 13.74% of the total assets and 19.55% of the net assets as of the end of 2024 [6]. - The valuation of Pengli Biopharmaceutical shows an increase of 5.25 billion yuan, with a valuation rate of 56.62% [5]. Group 2: Financial Performance of Target Company - Pengli Biopharmaceutical's revenue for 2023, 2024, and the first half of 2025 is projected to be 318 million yuan, 331 million yuan, and 187 million yuan, respectively, with net profits of 59.75 million yuan, 44.51 million yuan, and 23.86 million yuan [7]. - The gross profit margins for Pengli Biopharmaceutical are 47.3%, 42.98%, and 43.58% for the same periods, indicating a decline due to various factors [7]. - The performance commitment agreement stipulates that the target company must achieve net profits of at least 52 million yuan, 65 million yuan, and 78 million yuan for the years 2025 to 2027 [7]. Group 3: Independent Director's Concerns - Independent director Tao Hua'an has consistently voted against the acquisition, expressing that the company does not currently need to pursue mergers and acquisitions [9]. - The independent director's repeated opposition raises concerns about the transaction's acceptance and potential uncertainties [9]. - The board's approval of the revised acquisition proposal occurred despite the independent director's dissenting votes, indicating a divide in opinion regarding the merger's necessity [9].

Financial Overview - Revenue for H1 2025 reached 3,188 million RMB, an increase from 2,697 million RMB in H1 2024 [80] - Adjusted net profit for H1 2025 was 617 million RMB, up from 499 million RMB in H1 2024 [80] - Gross profit margin improved to 43.5%, up from 42.2% in H1 2024 [64] Performance Highlights - Gross margin increased by 1.3 percentage points to 43.5% [13] - Net profit growth outpaced revenue growth by 5.5 percentage points [14] - The company reported a backlog of orders worth 10.88 billion USD, with a year-on-year increase of over 40% [13] Segment Performance Small Molecule Business - Revenue for small molecule CDMO business was 24.29 billion RMB, a 10.6% increase year-on-year [20] - Gross margin for small molecule business reached 47.8%, up 0.6 percentage points [32] Emerging Business - Emerging business revenue surged by 51.2% to 7.56 billion RMB [19] - Gross margin for emerging business was 29.8%, an increase of 9.5 percentage points [20] Clinical CRO Business - Revenue for clinical CRO business was 1.39 billion RMB, reflecting a growth of 44.8% [42] - The company supported 13 projects to obtain clinical trial approvals in China [42] Market Expansion - The company added over 150 new CDMO business clients during the reporting period [22] - Revenue from the US market was 1.789 billion RMB, a slight increase of 0.5% year-on-year [25] - Revenue from the European market grew by over 200% to 548 million RMB [25] Future Outlook - The company anticipates a revenue growth of 13% to 15% for the full year of 2025 [77] - Plans to enhance operational efficiency and profitability, aiming for profit growth to exceed revenue growth [77] - Continued focus on expanding capabilities in peptide, oligonucleotide, and conjugated drug segments [77]

Group 1: Market Activity and Trends - The number of major asset restructuring plans disclosed by companies listed on the Sci-Tech Innovation Board has reached 105 since the introduction of the "Eight Policies for the Sci-Tech Innovation Board," with 44 plans disclosed this year, indicating high market activity [1] - Mergers and acquisitions (M&A) are seen as crucial for companies to integrate resources, strengthen core business development, and cultivate new growth points, thereby enhancing competitiveness [1][5] - The increase in M&A activity on the Sci-Tech Innovation Board is viewed positively, as it reflects a proactive approach to resource integration in emerging sectors [1][5] Group 2: Policy Support - Recent policies, including the "Eight Policies for the Sci-Tech Innovation Board" and "Six Policies for Mergers and Acquisitions," have significantly improved the flexibility and feasibility of M&A transactions, reducing costs and difficulties associated with corporate integration [1][7] - The China Securities Regulatory Commission (CSRC) has revised the "Management Measures for Major Asset Restructuring of Listed Companies," which marks the full implementation of the "Six Policies for Mergers and Acquisitions" at the institutional level [7][8] - Local governments, including Shanghai and Beijing, have introduced supportive policies to encourage M&A activities among listed companies, focusing on enhancing industrial chain integration [8] Group 3: Company-Specific Developments - Aopu Mai plans to acquire 100% of the shares of Pengli Biological through a combination of issuing shares and cash payments, aiming to enhance its client base in the biopharmaceutical sector [2] - Xunjie Xing is actively progressing with its plan to acquire 100% of the shares of Jiazhihong, with due diligence and related audit work underway [3] - Haiguang Information is planning a share swap merger with Zhongke Shuguang, which has a market value of 90.6 billion yuan, to achieve complementary advantages in the information industry [4] Group 4: Industry Insights - The fast-paced technological evolution and intense competition in emerging sectors make M&A a vital strategy for companies to quickly integrate resources and enhance industry synergy [5][6] - M&A can help companies acquire new technologies, talent, and markets, thereby strengthening their core competitiveness and facilitating industrial upgrades [5][9] - The current wave of M&A activity may face challenges, such as the risk of failing to achieve synergies post-acquisition and the potential for unfulfilled performance commitments from acquisition targets [9]

Core Viewpoint - Aopu Mai plans to acquire 100% equity of Pengli Bio for a total transaction price of 1.451 billion yuan, aiming to enhance its client resources in preclinical research and expand its early-stage drug development pipeline [1] Group 1 - The acquisition will be executed through a combination of issuing shares and cash payments to 31 transaction parties, including PLHK and Jiaxing Huituo [1] - The transaction is expected to allow the company to promote its cell culture products and biopharmaceutical CDMO services to clients at an early stage of drug development [1] - This strategic move aims to broaden the company's potential customer base and secure innovative drug pipelines with promising commercialization prospects [1]